Free tool
Drug Trial Radar: Dermatology
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
212
Completed, industry sponsors, Dermatology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed212
212 trials
Showing 1 to 25, recently updated first.
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03827798 · 248 participants · Start Feb 27, 2019 · Primary completion Dec 4, 2024
Drug: CFZ533; Placebo to CFZ533 and 9 more · For: Hidradenitis Suppurativa
Sites: Clearwater, Florida; Orange Park, Florida; Tampa, Florida · 36 sites in all
- Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
MoonLake Immunotherapeutics AGIndustry
NCT05322473 · 234 participants · Start Apr 25, 2022 · Primary completion May 9, 2023
Drug: Sonelokimab (M1095); Adalimumab · For: Hidradenitis Suppurativa
Sites: Fountain Valley, California; Los Angeles, California; Miami, Florida · 57 sites in all
Arctic TherapeuticsIndustry
NCT07774364 · 63 participants · Start Feb 2, 2026 · Primary completion Jul 15, 2026
Drug: AT-004; Placebo · For: Acne Vulgaris on the Face
Sites: Gandrup, Denmark; Herlev, Denmark; Vejle, Denmark
LEO PharmaIndustry
NCT04154293 · 34 participants · Start Dec 3, 2019 · Primary completion Aug 20, 2021
Drug: Isotretinoin · For: Congenital Ichthyosis
Sites: Phoenix, Arizona; Palo Alto, California; New Haven, Connecticut · 11 sites in all
- A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
Avalo Therapeutics, Inc.Industry
NCT06603077 · 253 participants · Start Sep 16, 2024 · Primary completion Feb 23, 2026
Drug: AVTX-009 Regimen 1; AVTX-009 Regimen 2 and 1 more · For: Hidradenitis Suppurativa
Sites: Scottsdale, Arizona; Tucson, Arizona; Northridge, California · 89 sites in all
CAGE Bio Inc.Industry
NCT04886739 · 78 participants · Start May 7, 2021 · Primary completion Dec 22, 2021
Drug: CGB-400; Vehicle Gel · For: Rosacea
Sites: Fremont, California
Aclaris Therapeutics, Inc.Industry
NCT05216224 · 95 participants · Start Dec 29, 2021 · Primary completion Dec 23, 2022
Drug: ATI-450; Placebo oral tablet · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Fort Smith, Arkansas; Encino, California · 20 sites in all
Sixera PharmaIndustry
NCT05211830 · 9 participants · Start Dec 7, 2021 · Primary completion Jun 10, 2025
Drug: SXR1096 cream; Placebo cream · For: Netherton Syndrome
Sites: Innsbruck, Austria; Paris, France; Freiburg im Breisgau, Germany · 5 sites in all
- Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle GelPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT04892706 · 686 participants · Start Jun 11, 2021 · Primary completion Sep 28, 2022
Drug: IDP-126 Gel; IDP-126 Vehicle Gel and 1 more · For: Acne Vulgaris
Sites: Bryant, Arkansas; Rogers, Arkansas; Fremont, California · 42 sites in all
- A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne VulgarisPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT04856917 · 123 participants · Start May 15, 2021 · Primary completion Feb 1, 2022
Drug: Imsidolimab; Placebo · For: Acne Vulgaris
Sites: Hot Springs, Arkansas; Fountain Valley, California; Sherman Oaks, California · 15 sites in all
- To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis SuppurativaPivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT04476043 · 209 participants · Start Aug 25, 2020 · Primary completion Dec 15, 2021
Drug: INCB054707; Placebo · For: Hidradenitis Suppurativa; Acne Inversa
Sites: Hoover, Alabama; Gilbert, Arizona; Phoenix, Arizona · 40 sites in all
- Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic KeratosisCompleted
TORQURIndustry
NCT06319794 · 46 participants · Start Apr 2, 2024 · Primary completion Jun 24, 2025
Drug: Bimiralisib; Bimiralisib · For: Actinic Keratosis
Sites: Basel, Switzerland; Lausanne, Switzerland
- Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne VulgarisPivotal-lookingCompleted
Ascletis Pharmaceuticals Co., Ltd.Industry
NCT05104125 · 180 participants · Start Jan 12, 2022 · Primary completion Apr 10, 2023
Drug: ASC40 25mg; ASC40 50mg and 2 more · For: Acne Vulgaris
Sites: Shanghai, China
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01474798 · 11 participants · Start Feb 29, 2012 · Primary completion Oct 31, 2012
Drug: RA-18C3 · For: Acne Vulgaris
Sites: Beverly Hills, California; St. Petersburg, Florida; Austin, Texas
- Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03852472 · 435 participants · Start Dec 21, 2018 · Primary completion Jan 14, 2021
Drug: Avacopan · For: Hidradenitis Suppurativa; Acne Inversa
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 91 sites in all
- Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic KeratosisPivotal-lookingCompleted
LEO PharmaIndustry
NCT01820260 · 395 participants · Start Apr 2013 · Primary completion Aug 2014
Drug: Ingenol mebutate gel; placebo · For: Actinic Keratosis
Sites: Carmel, Indiana
LEO PharmaIndustry
NCT01461655 · 40 participants · Start Nov 2011 · Primary completion Apr 2012
Drug: marketed topical retinoid; marketed topical NSAID and 2 more · For: Acne Vulgaris
Sites: Nice, France
- Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic KeratosisPivotal-lookingCompleted
LEO PharmaIndustry
NCT01998984 · 266 participants · Start Jan 2014 · Primary completion Jul 2014
Drug: ingenol mebutate · For: Actinic Keratosis
Sites: Smithtown, New York
LEO PharmaIndustry
NCT02305888 · 189 participants · Start Mar 2015 · Primary completion Jul 2015
Drug: LEO 43204 · For: Actinic Keratosis
Sites: Smithtown, New York
- Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe AcneCompleted
LEO PharmaIndustry
NCT02575950 · 59 participants · Start Jun 2016 · Primary completion Apr 2017
Drug: LEO43204; Placebo · For: Acne Vulgaris
Sites: Lomita, California
- Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic KeratosisPivotal-lookingCompleted
LEO PharmaIndustry
NCT02100813 · 220 participants · Start May 2014 · Primary completion Mar 2015
Drug: LEO 43204; Placebo · For: Actinic Keratosis
Sites: Snellville, Georgia
- A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic KeratosisPivotal-lookingCompleted
LEO PharmaIndustry
NCT01922050 · 320 participants · Start Oct 2013 · Primary completion Nov 2014
Drug: LEO 43204 Formulation 1; LEO 43204 Formulation 2 and 6 more · For: Actinic Keratosis
Sites: Phoenix, Arizona; Lomita, California; San Diego, California · 25 sites in all
- Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic KeratosisPivotal-lookingCompleted
LEO PharmaIndustry
NCT02120456 · 224 participants · Start May 2014 · Primary completion May 2015
Drug: LEO 43204; Placebo · For: Actinic Keratosis
Sites: Phoenix, Arizona; Lomita, California; San Diego, California · 21 sites in all
LEO PharmaIndustry
NCT01803477 · 37 participants · Start Feb 2013 · Primary completion Oct 2013
Drug: once daily for two consecutive days (Picato) · For: Actinic Keratosis
Sites: Woolloongabba, Australia · 2 sites in all
- Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular RosaceaPivotal-lookingCompleted
Alfasigma S.p.A.Industry
NCT05150587 · 216 participants · Start Oct 5, 2021 · Primary completion Oct 20, 2022
Drug: Rifaximin; Placebo · For: Papulopustular Rosacea
Sites: Yuma, Arizona; Fort Smith, Arkansas; Long Beach, California · 38 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.